BLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
3
Mechanism of Action
Interleukin-13 Antagonists
Pharmacologic Class:
Interleukin-13 Antagonist
Indications (3)
Clinical Trials (3)
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
Started Jan 2023
90 enrolled
Atopic Dermatitis
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Started Jun 2020
1,153 enrolled
Atopic Dermatitis
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Started Feb 2020
206 enrolled
Atopic Dermatitis